Filtered By:
Drug: Activase

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Does Sex Influence the Response to Intravenous Thrombolysis in Ischemic Stroke?: Answers From Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register Clinical Sciences
Conclusions— Data from Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register suggest that intravenous thrombolysis may modify the observed survival and recovery advantage for men expected in the natural course of an ischemic stroke, with a possible larger beneficial treatment effect in women when compared with men.
Source: Stroke - November 25, 2013 Category: Neurology Authors: Lorenzano, S., Ahmed, N., Falcou, A., Mikulik, R., Tatlisumak, T., Roffe, C., Wahlgren, N., Toni, D., on behalf of the SITS Investigators Tags: Clinical Sciences Source Type: research

Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis Brief Reports
Conclusions— Clinicians are poor at approximating the weights of patients with stroke in the acute setting, especially when patients lie at the extremes of weight. Beds capable of weighing patients should be mandated in emergency rooms for patients with acute stroke.
Source: Stroke - December 28, 2015 Category: Neurology Authors: Barrow, T., Khan, M. S., Halse, O., Bentley, P., Sharma, P. Tags: Treatment Brief Reports Source Type: research

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association AHA/ASA Scientific Statement
Purpose— To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of altepla...
Source: Stroke - January 25, 2016 Category: Neurology Authors: Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., Saposnik, G., Saver, J. L., Smith, E. E., on behalf of the American Heart Association Stro Tags: Statements and Guidelines AHA/ASA Scientific Statement Source Type: research

Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner Original Articles
Conclusions— Taking the patient to CT on the emergency medical services stretcher, registering the patient as unknown, STAT stroke protocol, and administering alteplase in CT are associated with lower DTN time.
Source: Circulation: Cardiovascular Quality and Outcomes - January 16, 2017 Category: Cardiology Authors: Kamal, N., Holodinsky, J. K., Stephenson, C., Kashayp, D., Demchuk, A. M., Hill, M. D., Vilneff, R. L., Bugbee, E., Zerna, C., Newcommon, N., Lang, E., Knox, D., Smith, E. E. Tags: Quality and Outcomes, Ischemic Stroke Original Articles Source Type: research

Protocol for the perfusion and angiography imaging sub‐study of the Third International Stroke Trial (IST‐3) of alteplase treatment within six‐hours of acute ischemic stroke
RationaleIntravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes in patients treated early after stroke but at the risk of causing intracranial hemorrhage. Restricting recombinant tissue Plasminogen Activator use to patients with evidence of still salvageable tissue, or with definite arterial occlusion, might help reduce risk, increase benefit and identify patients for treatment at late time windows. AimsTo determine if perfusion or angiographic imaging with computed tomography or magnetic resonance help identify patients who are more likely to benefit from recombinant tissue Plasminogen Ac...
Source: International Journal of Stroke - January 22, 2013 Category: Neurology Authors: Joanna M. Wardlaw, Rudiger Kummer, Trevor Carpenter, Mark Parsons, Richard I. Lindley, Geoff Cohen, Veronica Murray, Adam Kobayashi, Andre Peeters, Francesca Chappell, Peter A. G. Sandercock Tags: Protocols Source Type: research

Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third International Stroke Trial) Clinical Sciences
Conclusions— These exploratory analyses of the third International Stroke Trial (IST-3) trial support improving acute stroke patients’ access to earlier alteplase treatment, treatment of patients with poor prognosis, and further randomized controlled trials in minor stroke to replicate these findings. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
Source: Stroke - November 24, 2014 Category: Neurology Authors: Whiteley, W. N., Thompson, D., Murray, G., Cohen, G., Lindley, R. I., Wardlaw, J., Sandercock, P., on behalf of the IST-3 Collaborative Group Tags: Acute Cerebral Infarction, Thrombolysis Clinical Sciences Source Type: research

Analysis of Run Sheets of EMS Serving a Metropolitan Comprehensive Stroke Center (P1.268)
Conclusions:Patients with acute stroke transported by EMS have better quality metrics and higher chance of receiving acute treatment. EMS documented assessment allows for the diagnosis or stroke in general but cannot identify LVO because the assessment of cortical signs is very limited.Disclosure: Dr. Hussein has nothing to disclose. Dr. Kashyap has nothing to disclose. Dr. Erickson has nothing to disclose. Dr. Forsberg has nothing to disclose. Dr. Burnett has nothing to disclose. Dr. Stanfield has nothing to disclose. Dr. Wewerka has nothing to disclose. Dr. Terwilliger has nothing to disclose. Dr. Hanson has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Hussein, H., Kashyap, B., Erickson, L., Forsberg, A., Burnett, A., Stanfield, S., Wewerka, S., Terwilliger, A., Hanson, L. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Details of a prospective protocol for a collaborative meta‐analysis of individual participant data from all randomized trials of intravenous rt‐PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists’ Collaborative meta‐analysis
We describe the protocol for an updated individual patient data meta‐analysis of trials of intravenous alteplase, including results from the recently reported third International Stroke Trial, in which a wide range of patients enrolled up to six‐hours after stroke onset were randomized to alteplase vs. control. Study OutcomesThis protocol will specify the primary outcome for efficacy, specified prior to knowledge of the results from the third International Stroke Trial, as the proportion of patients having a ‘favorable’ stroke outcome, defined by modified Rankin Score 0–1 at final follow‐up at three‐ to six...
Source: International Journal of Stroke - April 1, 2013 Category: Neurology Tags: Protocol Source Type: research

Intravenous Thrombolysis with Neuroprotective Therapy by Edaravone for Ischemic Stroke Patients Older than 80 Years of Age
Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan.Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical bac...
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2013 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Hisashi Narai, Yasuhiro Manabe, Yoshiki Takao, Sanami Kawada, Kenichi Kashihara, Yasushi Takehisa, Satoshi Inoue, Hideki Kiriyama, Koji Abe Tags: Original Articles Source Type: research

Within-Day and Weekly Variations of Thrombolysis in Acute Ischemic Stroke: Results From Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register Clinical Sciences
Conclusions— Frequency of thrombolytic treatment seems to follow the same circadian pattern of stroke incidence, whereas its correspondence to a weekly pattern is less clear. Time of treatment is an independent predictor of outcome.
Source: Stroke - December 23, 2013 Category: Neurology Authors: Lorenzano, S., Ahmed, N., Tatlisumak, T., Gomis, M., Davalos, A., Mikulik, R., Sevcik, P., Ollikainen, J., Wahlgren, N., Toni, D., for the SITS Investigators Tags: Acute Cerebral Infarction, Thrombolysis Clinical Sciences Source Type: research

Unfavorable Outcome of Thrombolysis in Chinese Patients with Cardioembolic Stroke: a Prospective Cohort Study.
CONCLUSIONS: Patients with cardioembolic stroke had more SICH after thrombolysis, and worse clinical outcome at 3-month follow-up compared with those with LAA. This emphasizes the importance of preventing cardioembolism. PMID: 26096605 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - June 20, 2015 Category: Neuroscience Authors: Wang XG, Zhang LQ, Liao XL, Pan YS, Shi YZ, Wang CJ, Wang YL, Liu LP, Zhao XQ, Wang YJ, Li D, Wang CX, Thrombolysis Implementation and Monitoring of acute ischemic Stroke in China (TIMS-China) Investigators Tags: CNS Neurosci Ther Source Type: research

Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis Brief Reports
Conclusions— This post hoc analysis in a highly selected sample of IST-3 supports the rationale of A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS) trial—a randomized, phase IIIb study to evaluate IV r-tPA in mild ischemic stroke.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Khatri, P., Tayama, D., Cohen, G., Lindley, R. I., Wardlaw, J. M., Yeatts, S. D., Broderick, J. P., Sandercock, P., on behalf of the PRISMS and IST-3 Collaborative Groups Tags: Thrombolysis Brief Reports Source Type: research

Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial
Conclusions: In thrombolysis-treated patients with acute ischemic stroke, seizures are uncommon, occur early, and predict poor recovery. Clinicaltrials.gov identifier: NCT01422616.
Source: Neurology Clinical Practice - August 14, 2017 Category: Neurology Authors: Xu, Y., Hackett, M. L., Chalmers, J., Lindley, R. I., Wang, X., Li, Q., Robinson, T., Arima, H., Lavados, P. M., Anderson, C. S., For the ENCHANTED Study Group Tags: Quality of life, All Cerebrovascular disease/Stroke, Prevalence studies, Infarction, All Epilepsy/Seizures Research Source Type: research

Determinants of Early Outcomes in Patients with Acute Ischemic Stroke and Proximal Artery Occlusion (S02.005)
CONCLUSIONS: In acute ischemic stroke patients thought LTB from IAT, IV tPA independently predicted favorable early post-stroke outcomes. These data reinforce the recommendation to provide early, rapid IV tPA to all eligible patients. Further studies are warranted to explore the lack of IAT effect seen in this study, which may be due to small sample size, residual confounding, or interaction between the IV tPA and IAT.Disclosure: Dr. Labuzetta has nothing to disclose. Dr. Yoo has received research support from Penumbra Inc. Dr. Ali has nothing to disclose. Dr. Fitzpatrick has nothing to disclose. Dr. Hirsch has nothing to ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Labuzetta, J., Yoo, A., Ali, S., Fitzpatrick, K., Hirsch, J., Schwamm, L., Rost, N. Tags: S02 Acute Stroke Therapy Source Type: research

Clinical relevance and practical implications of trials of perfusion and angiographic imaging in patients with acute ischaemic stroke: a multicentre cohort imaging study
Conclusion Early recanalisation on angiography appeared to predict clinical outcome more directly than did tissue reperfusion. Acute assessment with CT and follow-up with MR was practical and feasible, did not preclude image analysis, and would enhance trial recruitment and generalisability of results.
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 6, 2013 Category: Neurosurgery Authors: Wardlaw, J. M., Muir, K. W., Macleod, M.-J., Weir, C., McVerry, F., Carpenter, T., Shuler, K., Thomas, R., Acheampong, P., Dani, K., Murray, A. Tags: Open access, Stroke, Radiology, Radiology (diagnostics) Cerebrovascular disease Source Type: research